Therefore, future research should focus on the potential treatment effect of SGLT2 inhibitors and the application of SGLT2 inhibitors in diabetic cardiomyopathy; in addition, the CV effects of other antihyperglycemic agents have also been assessed, with more high-quality basic research conducted to further clarify the potential related mechanisms. Here, SLC5A2 is linked to diabetic cardiomyopathy.